risedronate tablet
sanis health inc - risedronate sodium (risedronate sodium monohydrate) - tablet - 35mg - risedronate sodium (risedronate sodium monohydrate) 35mg - bone resorption inhibitors
risedronate tablet
sanis health inc - risedronate sodium (risedronate sodium hemipentahydrate) - tablet - 150mg - risedronate sodium (risedronate sodium hemipentahydrate) 150mg
pms-risedronate plus calcium tablet
pharmascience inc - risedronate sodium (risedronate sodium hemipentahydrate); calcium (calcium carbonate) - tablet - 35mg; 500mg - risedronate sodium (risedronate sodium hemipentahydrate) 35mg; calcium (calcium carbonate) 500mg - bone resorption inhibitors
auro-risedronate tablet
auro pharma inc - risedronate sodium (risedronate sodium hemipentahydrate) - tablet - 5mg - risedronate sodium (risedronate sodium hemipentahydrate) 5mg - bone resorption inhibitors
auro-risedronate tablet
auro pharma inc - risedronate sodium (risedronate sodium hemipentahydrate) - tablet - 30mg - risedronate sodium (risedronate sodium hemipentahydrate) 30mg - bone resorption inhibitors
auro-risedronate tablet
auro pharma inc - risedronate sodium (risedronate sodium hemipentahydrate) - tablet - 150mg - risedronate sodium (risedronate sodium hemipentahydrate) 150mg - bone resorption inhibitors
risedronate tablet
sanis health inc - risedronate sodium (risedronate sodium monohydrate) - tablet - 5mg - risedronate sodium (risedronate sodium monohydrate) 5mg - bone resorption inhibitors
risedronate tablet
sanis health inc - risedronate sodium (risedronate sodium monohydrate) - tablet - 30mg - risedronate sodium (risedronate sodium monohydrate) 30mg - bone resorption inhibitors
q-risedronate tablet
qd pharmaceuticals ulc - risedronate sodium (risedronate sodium hemipentahydrate) - tablet - 35mg - risedronate sodium (risedronate sodium hemipentahydrate) 35mg - bone resorption inhibitors
risedronate sodium tablet, film coated
proficient rx lp - risedronate sodium (unii: ofg5exg60l) (risedronic acid - unii:km2z91756z) - risedronate sodium tablets, usp are indicated for the treatment and prevention of osteoporosis in postmenopausal women. in postmenopausal women with osteoporosis, risedronate sodium tablets, usp reduce the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis-related fractures [see clinical studies (14.1, 14.2) ]. risedronate sodium tablets, usp are indicated for treatment to increase bone mass in men with osteoporosis. risedronate sodium tablets, usp are indicated for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoid treatment (daily dosage of greater than or equal to 7.5 mg of prednisone or equivalent) for chronic diseases. patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin d. risedronate sodium tablets, usp are indicated for treatment of paget’s disease of bone in men and women. the optimal duration of use has not been determined. the